Antibiotic Can Reduce Hospitalization, Prevent Recurrence of Rare Brain Disorder, Analysis Shows

Mar 26, 2010

(PhysOrg.com) -- A study analysis by researchers at the University of Cincinnati confirms that the antibiotic rifaximin can reduce hospitalizations for patients and prevent the recurrence of a certain brain disorder caused by liver failure.

A study analysis by researchers at the University of Cincinnati confirms that the antibiotic rifaximin can reduce hospitalizations for patients and prevent the recurrence of a certain brain disorder caused by .

These findings were reported in the March 25, 2010, edition of the .

Guy Neff, MD, lead investigator on the study locally and associate professor of medicine, and transplant, with colleagues in the digestive diseases division, found that rifaximin significantly reduced the risk of hepatic encephalopathy-related hospitalizations when compared to a placebo drug.

In addition, over a six-month period, treatment with rifaximin helped patients maintain remission for hepatic encephalophaty more effectively than the placebo.

Hepatic encephalopathy, or HE, is a potentially reversible neuropsychiatric abnormality that can result due to liver failure.

"When there is severe damage to the liver, toxic substances that are normally removed by the liver accumulate in the blood and impair the brain,” says Neff, director of liver transplantation and a specialist with UC Health. "Signs of HE can include impaired cognition, asterixis—or a wrist tremor—and a decreased level of consciousness including coma, cerebral edema and possibly death.”

Rifaximin is approved to treat traveler’s diarrhea. On March 24, 2010, the U.S. also approved this drug for the unrestricted treatment of HE—the first new treatment for the disorder in over 30 years.

Researchers analyzed a randomized, double-blind, placebo-controlled study of 299 patients with a history of HE—meaning patients and researchers were not told whether they were receiving/giving rifaximin or the placebo drug.

They found that patients who took rifaximin as opposed to the placebo had about 50 percent less risk of being hospitalized; also, approximately 58 percent of patients given the drug did not experience recurrence of HE.

"This new data solidly supports the clinical efficacy of rifaximin in reducing the risk of HE-related hospitalization and its ability to prevent patients from redeveloping the illness,” Neff says. "As demonstrated in previously published pharmacoeconomic data, reducing recurrent HE events may reduce the need for HE-related hospitalization, thereby potentially decreasing the costs of care, and improving patients' quality of life.”

Neff has received honoraria from the makers of rifaximin.

Explore further: Restrictions lifted at British bird flu farm

More information: Study paper: content.nejm.org/cgi/reprint/362/12/1071.pdf

add to favorites email to friend print save as pdf

Related Stories

Ibuprofen restores learning ability in rats with liver failure

Aug 01, 2007

Cognitive impairment is one of the neurological effects in patients with hepatic encephalopathy (abnormal brain function due to severe liver disease). For the first time, a new study showed that treatment with an anti-inflammatory ...

Mayo Clinic seeks new therapies for alcoholic hepatitis

Dec 01, 2008

A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study ...

Recommended for you

Restrictions lifted at British bird flu farm

17 hours ago

Britain on Sunday lifted all restrictions at a duck farm in northern England after last month's outbreak of H5N8 bird flu, the same strain seen in recent cases across Europe.

Recorded Ebola deaths top 7,000

Dec 20, 2014

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

Dec 20, 2014

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.